A detailed history of Barclays PLC transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, Barclays PLC holds 324,472 shares of XERS stock, worth $1.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
324,472
Previous 324,472 -0.0%
Holding current value
$1.1 Million
Previous $925,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

BUY
$2.06 - $2.96 $312,471 - $448,987
151,685 Added 87.79%
324,472 $925,000
Q2 2024

Aug 14, 2024

SELL
$1.7 - $2.45 $54,716 - $78,855
-32,186 Reduced 15.7%
172,787 $389,000
Q1 2024

May 15, 2024

SELL
$2.04 - $3.22 $144,819 - $228,587
-70,990 Reduced 25.72%
204,973 $453,000
Q4 2023

Feb 15, 2024

BUY
$1.47 - $2.36 $250,223 - $401,719
170,220 Added 160.98%
275,963 $648,000
Q3 2023

Nov 07, 2023

BUY
$1.8 - $2.69 $23,472 - $35,077
13,040 Added 14.07%
105,743 $197,000
Q2 2023

Aug 03, 2023

SELL
$1.82 - $2.98 $85,592 - $140,146
-47,029 Reduced 33.66%
92,703 $242,000
Q1 2023

May 04, 2023

BUY
$1.03 - $1.63 $32,363 - $51,216
31,421 Added 29.01%
139,732 $229,000
Q4 2022

Feb 13, 2023

BUY
$1.14 - $1.65 $54,225 - $78,483
47,566 Added 78.3%
108,311 $144,000
Q3 2022

Nov 03, 2022

BUY
$1.37 - $1.93 $42,676 - $60,121
31,151 Added 105.26%
60,745 $95,000
Q2 2022

Aug 12, 2022

BUY
$1.48 - $2.64 $11,552 - $20,607
7,806 Added 35.83%
29,594 $46,000
Q1 2022

May 16, 2022

BUY
$2.0 - $2.87 $43,576 - $62,531
21,788 New
21,788 $56,000

Others Institutions Holding XERS

About Xeris Biopharma Holdings, Inc.


  • Ticker XERS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,956,992
  • Market Cap $462M
  • Description
  • Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...
More about XERS
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.